HUA Medicine is a pharmaceutical company focused on the development and commercialization of oral drugs for the treatment of diabetes. Its core product, dorzagliatin (HMS5552), is a first-in-class glucokinase activator approved in mainland China, Hong Kong, and Macau for the treatment of Type 2 diabetes. The company markets dorzagliatin under the brand name HuaTangNing in mainland China and MYHOMSIS in Hong Kong and Macau. HUA Medicine in-licensed global rights to dorzagliatin from Roche and previously partnered with Bayer for commercialization in China before assuming full responsibility for sales in 2025. The company is developing a second-generation glucokinase activator for obesity and metabolic diseases, with clinical trials underway in the United States. Its pipeline also includes a fixed-dose combination of dorzagliatin with metformin, as well as potential applications for dorzagliatin in diabetes prevention, MODY-2, and neurodegenerative conditions. HUA Medicine was founded in 2010 and operates through subsidiaries in the United States and Hong Kong.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage huamedicine.com
Sector Healthcare IR page huamedicine.com/investor
Tags
glucokinase activators, type 2 diabetes, metabolic diseases, obesity, oral antidiabetic drugs, diabetes prevention, mody-2, neurodegenerative diseases, drug discovery, clinical trials, dorzagliatin, HMS5552, HuaTangNing, MYHOMSIS, 2nd Generation GKA, mGluR5 NAM, Hua Medicine US, Nanjing Shengde Ruier Pharmaceutical Technology Co. Ltd.
Press page —

Metrics

Valuation  
Market cap HK$ 2.15B
Market cap (USD) $ 273.999M
P/E 1.62
PEG —
P/BV 1.70
P/S 2.79
P/OCF -59.84
P/FCF —
Dividend yield —
Turnover / mcap 0.05%
Returns  
ROE 109.9%
ROI 88.0%
ROIC 88.0%
Profit margin 224.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 25.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 492.934M 255.892M 76.61M 17.599M 0 0 — — —
Net profit 1.106B -250.144M -211.234M -203.507M -325.734M -393.134M -425.27M -3.603B -272.714M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 3.02 — — 2.41 3.95 5.66 4.77 — —
Price performance 12m — — — -0.42 -0.25 0.19 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

致登记股东之通知信函及回条 了解更多 Bull 0 Bear 0 Routine

HUA MEDICINE 華領醫藥

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock code 股份代號: 2552)

NOTIFICATION LETTER 通知信函 24 September 2026 Dear Registered Shareholders, Hua Medicine (the “Company”) – Notice of publication of Interim Report 2026 (the “Current Corporate Communication”) The English and Chinese versions of the Company’s Current Corporate Communications are now available on the Company’s website at www.huamedicine.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications(Note) . If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited (“Branch Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to [email protected]. The Company will send the Current Corporate Communications to you in printed form free of charge upon your request. It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the abovementioned address by post or by email to [email protected]. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications (“Notice of Publication”) and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form. Should you have any queries relating to this notification, please call the Branch Share Registrar’s telephone hotline at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays). Yours faithfully Hua Medicine Dr. Li Chen Chief Executive Officer and Executive Director Note:

Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東: 華領醫藥(「本公司」) — 中期報告2026(「本次公司通訊」)之刊發通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.huamedicine.com)及香港聯合交易所有限公司(「聯交所」)之網站(www.hkexnews.hk)(「網站版本」)。我們建 議閣下閱覽本公司本次及日後公司通訊(附註)的網站版本。 如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本及欲索取本次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附之回條,並以已預付郵費的郵寄 標籤寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳證券登記有限公司(地址為香港夏慤道16號遠東金融中心17樓) (如在香港投寄毋須貼上郵票),或電郵至 [email protected] 。本公司會因應閣下之要求寄上公司通訊的印刷本,費用全免。 登記股東有責任提供有效的電子郵件地址。如閣下尚未提供閣下之電子郵件地址予本公司,或需更新閣下之電子郵件地址,本公司建議閣下填妥及簽署隨附之回條,並按 上述地址以郵寄方式交回本公司的股份過戶登記分處或以電郵方式發送至[email protected]。如果本公司沒有收到閣下的有效電子郵件地址, 閣下將無法透過電子郵件方 式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本公司只能以印刷本方式向閣下發送登載通知及可供採取行動的公司通訊之 印刷本予閣下,直至股份過戶登記分處收到閣下有效的電子郵件地址為止。 倘

閣下對本通知有任何查詢,請於星期一至星期五(公眾假期除外)上午9時至下午6時,致電股份過戶登記分處熱線 (852) 2980 1333。 華領醫藥 行政總裁兼執行董事 陳力博士 謹啓

2026年9月24日 附註:

公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於 (a) 董事會報告,公司年度賬目連同核數師報告以及(如適用)財務摘要報告; (b) 中期報告及(如適用)中期摘要報告; (c) 季度報告(如有); (d) 會議通告; (e) 上市文件; (f) 通函;及 (g) 代表委任表格。 可供採取行動的公司通訊是指任何涉及要求股東指示其擬如何行使其有關股東權利的公司通訊。

Registered Shareholder’s information (English name and address) 登記股東資料(英文姓名及地址)

REPLY FORM 回條 To:

致:

Hua Medicine (the “Company”) (Stock Code: 2552) (Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

華領醫藥(「本公司」) (股份代號:2552) (於開曼群島註冊成立的有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓

I/We would like to receive the Current Corporate Communication and all future Corporate Communications and Actionable Corporate Communications in printed form in the manner indicated below: 本人 ╱ 我們現欲以下列方式收取本次公司通訊及將來所有公司通訊及可供採取行動的公司通訊之印刷本: (Please mark“✓”in ONLY ONE of the following boxes 請從下列選擇中,僅在其中一個空格內劃上「✓」號) Part A 甲部

I/We would like to receive a printed copy in the English language only; OR 本人 ╱ 我們現欲收取一份英文印刷本;或 I/We would like to receive a printed copy in the Chinese language only; OR 本人 ╱ 我們現欲收取一份中文印刷本;或 I/We would like to receive a printed copy in both the English language and the Chinese language. 本人 ╱ 我們現欲收取英文和中文各一份印刷本。 I/We would like to receive all future Corporate Communications and Actionable Corporate Communications in electronic form via the email address below: 本人 ╱ 我們現欲以以下電郵地址電子郵件方式收取本公司所有將來的公司通訊及可供採取行動的公司通訊的登載通知:

Part B 乙部

(Please provide the email address in English Capital Letters) (請以英文正楷填寫電郵地址) Name(s) of Shareholder(s):

Signature:

(Please use BLOCK LETTERS 請用正楷填寫)

股東姓名:

簽名:

Address:

(Please use BLOCK LETTERS 請用正楷填寫)

地址:

HUA MEDICINE 華領醫藥

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock code 股份代號: 2552)

NOTIFICATION LETTER 通知信函 24 September 2026 Dear Non-registered Holder(s)

(Note 1)

,

Hua Medicine (the “Company”) – Notice of publication of Interim Report 2026 (the “Current Corporate Communication”) The English and Chinese versions of the Company’s Current Corporate Communications are available on the Company’s website at www.huamedicine.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of Current Corporate Communication. If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications(Note 2) in printed form, please complete, sign the enclosed Request Form and return it to the Company branch share registrar in Hong Kong, Tricor Investor Services Limited (“Branch Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to [email protected]. The Company will send the Current Corporate Communication to you in printed form free of charge upon request. As a non-registered holder of the Company, a notice of publication of the Website Version of a Corporate Communication, in both English and Chinese, will be sent by the Company to you by email or by post, only if your email address or postal address (as the case may be) are provided to the Company by your banks, brokers, custodians, nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the “Intermediaries”). In support of electronic communication by email, nonregistered holders are recommended to provide their functional email addresses to their Intermediaries. If the Company does not receive your functional email address or postal address from your Intermediaries via HKSCC Nominees Limited, no notice of publication of the Website Version of a Corporate Communication will be sent to you. Should you have any queries relating to any of the above matters, please call the Branch Share Registrar’s telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday (excluding public holidays). Yours faithfully Hua Medicine Dr. Li Chen Chief Executive Officer and Executive Director Note: 1.

Non-Registered Holder means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications of the Company. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; and (f) a circular.

各位非登記股東(附註1): 華領醫藥(「本公司」) — 中期報告2026(「本次公司通訊」)之刊發通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.huamedicine.com)及香港聯合交易所有限公司(「聯交所」)之網站(www.hkexnews.hk)(「網站版本」)。本公司 建議閣下閱覽本公司本次公司通訊的網站版本。 如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本,及欲索取本次及將來公司通訊(附註2)的印刷本,請填妥及簽署隨附之申請表格,並以已預付郵費的郵 寄標籤寄回本公司之香港股份過戶登記分處(「股份過戶登記分處」)卓佳證券登記有限公司(地址為香港夏慤道16號遠東金融中心17樓) (如在香港投寄毋須貼上郵票),或電郵至 [email protected]。本公司會因應閣下之要求寄上公司通訊的印刷本,費用全免。 作為本公司之非登記股東,本公司將透過電子郵件方式或郵寄方式(僅於代閣下持有股份的銀行、經紀人、託管人、代理人或香港中央結算(代理人)有限公司(統稱「中介機 構」)向本公司提供閣下的電郵地址或郵寄地址的情況下)向閣下發出發佈公司通訊網站版本的登載通知(包括英文及中文版本)。為了可透過電郵進行電子通訊,建議非登記 股東向其中介機構提供其有效的電郵地址。如本公司沒有收到閣下的中介機構透過香港中央結算(代理人)有限公司提供閣下的有效的電郵地址或郵寄地址,本公司將不會 向閣下發送登載通知。 倘

閣下對本通知有任何查詢,請於星期一至星期五(公眾假期除外)上午9時至下午6時,致電股份過戶登記分處熱線(852)2980 1333。 華領醫藥 行政總裁兼執行董事 陳力博士 謹啓

2026年9月24日 附註: 1. 2.

非登記股東指其股份存放於中央結算及交收系統(中央結算及交收系統)的有關人士或公司,而彼等已透過香港中央結算有限公司不時通知本公司,彼等擬收取本公司之公司通訊。 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度賬目連同核數師報告以及(如適用)財務摘要報告;(b)中 期報告及(如適用)中期摘要報告;(c)季度報告(如有);(d)會議通告;(e)上市文件;及(f)通函。

Non-Registered Holder’s information (English name and address) 非登記股東資料(英文姓名及地址)

REQUEST FORM 申請表格 To:

致:

Hua Medicine (the “Company”) (Stock Code: 2552) (Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

華領醫藥(「本公司」) (股份代號:2552) (於開曼群島註冊成立的有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓

REMINDER 提示 As a non-registered holder, if you wish to receive Corporate Communications(1) pursuant to the Listing Rules(2), you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries. 作為非登記股東,如有意根據《上市規則》(2) 收取公司通訊 (1), 閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港 中央結算(代理人)有限公司(統稱「中介公司」),並向閣下的中介公司提供閣下的電子郵件地址。 I/We would like to receive the Current Corporate Communications and all future Corporate Communications of the Company in the manner as indicated below: 本人 ╱ 我們現在希望以下列方式收取本公司本次及將來所有公司通訊文件: (Please mark a“✓”in ONLY ONE of the following boxes)(請從下列選擇中,僅在其中一個空格內劃上「✓」號) to receive a printed copy in the English language only; OR 僅收取英文印刷本;或 to receive a printed copy in the Chinese language only; OR 僅收取中文印刷本;或 to receive a printed copy in both the English language and the Chinese language. 同時收取英文及中文印刷本。 Signature:

Date:

簽署:

日期 :

Name:

证券变动月报表 了解更多 Bull 0 Bear 0 Routine

FF301

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份:

2026年8月31日

狀態: 新提交

致:香港交易及結算所有限公司 公司名稱:

華領醫藥

呈交日期:

2026年9月4日

I. 法定/註冊股本變動

  1. 股份分類

普通股

股份類別

不適用

證券代號 (如上市)

02552

說明

普通股

於香港聯交所上市 (註1)

面值

法定/註冊股份數目 上月底結存

2,000,000,000 USD

法定/註冊股本 0.001 USD

2,000,000

USD

增加 / 減少 (-) 本月底結存

是

2,000,000,000 USD 本月底法定/註冊股本總額: USD

第 1 頁共 10 頁

0.001 USD

2,000,000 2,000,000

v 1.2.1

FF301

II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認

  1. 股份分類

普通股

股份類別

不適用

證券代號 (如上市)

02552

說明

普通股

增加 / 減少 (-) 本月底結存

是

庫存股份數目

已發行股份(不包括庫存股份)數目 上月底結存

於香港聯交所上市 (註1)

已發行股份總數

1,056,605,016

0

0

0

1,056,605,016

0

1,056,605,016

1,056,605,016

足夠公眾持股量的確認(註4) 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條,我們在此確認,就上述所列股份類別而言,截至本月底: ✔

已符合適用的公眾持股量要求(見下方) 未符合適用的公眾持股量要求(見下方)

根據《主板上市規則》第13.32B條或第19A.28B條 / 《GEM上市規則》第17.37B條或第25.21B條(視情況而定)所載的有關股份類別的最低公眾持股量要求為: 適用的公眾持股量門檻

初始指定門檻 - 上市股份所屬類別的已發行股份總數(不包括庫存股份)的25%

額外信息

第 2 頁共 10 頁

v 1.2.1

FF301

III.已發行股份及/或庫存股份變動詳情 (A). 股份期權(根據發行人的股份期權計劃)

  1. 股份分類

普通股

股份類別

證券代號(如上市)

02552

說明

股份期權計劃詳情

1).

首次公開發售後購股權 計劃(於 26/08/2018通過 並於14/09/2018生效)

上月底結存的股份期權數 目

不適用

本月底結存的股份期權數 目

本月內變動

77,317,132 已授出

200,000

已失效

-2,708

是

於香港聯交所上市 (註1)

本月內因此發行的新股數 目 (A1)

本月内因此自庫存轉讓的 庫存股份數目 (A2)

本月底因此可能發行或自 庫存轉讓的股份數目

77,514,424

本月底可於所有根據計劃 授出的股份期權予以行使 時發行或自庫存轉讓的股 份總數 16,710,610

股東大會通過日期 (如適用)

增加已發行股份(不包括庫存股份):

普通股 (AA1)

減少庫存股份:

普通股 (AA2)

本月內因行使期權所得資金總額: HKD

第 3 頁共 10 頁

0

v 1.2.1

FF301 (B). 承諾發行發行人股份的權證

不適用

第 4 頁共 10 頁

v 1.2.1

FF301 (C). 可換股票據(即可轉換為發行人股份)

不適用

第 5 頁共 10 頁

v 1.2.1

FF301 (D). 為發行發行人股份所訂立的任何其他協議或安排,包括期權(但不包括根據股份期權計劃發行的期權)

第 6 頁共 10 頁

不適用

v 1.2.1

FF301 (E). 已發行股份及/或庫存股份的其他變動

不適用

本月内合共增加/減少(-)已發行股份 (不包括庫存股份) 總額 (即AA1至EE1項的總和) :

普通股

本月内合共增加/減少(-)庫存股份總額 (即AA2至EE2項的總和) :

普通股

第 7 頁共 10 頁

v 1.2.1

FF301

IV. 有關香港預託證券(預託證券)的資料

不適用

第 8 頁共 10 頁

v 1.2.1

FF301

V. 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條,我們在此確認,據我們所知所信,發行人在本月的每項證券發行或庫存股份出售或轉讓(如第III部及第IV部所述但未曾於根據 《主板上市規則》第13.25A條 /《GEM上市規則》第17.27A條所刊發的報表中披露)已獲發行人董事會正式授權批准,並遵照所有適用上市規則、法律及其他監管規定進行,並在適用的情況下: (註5) (i)

上市發行人已收取其在是次證券發行或庫存股份出售或轉讓應得的全部款項;

(ii)

《香港聯合交易所有限公司證券上市規則》「上市資格」項下所規定有關上市的一切先決條件已全部履行;

(iii)

批准證券上市買賣的正式函件內所載的所有條件(如有)已予履行;

(iv)

每類證券在各方面均屬相同(註6);

(v)

《公司(清盤及雜項條文)條例》規定送呈公司註冊處處長存檔的全部文件已經正式存檔,而一切其他法律規定亦已全部遵行;

(vi)

確實所有權文件按照發行、出售或轉讓條款的規定經已發送/現正準備發送/正在準備中並將會發送;

(vii)

發行人的上市文件所示已由其購買或同意購買的全部物業的交易已完成;全部該等物業的購買代價已予繳付;及

(viii)

有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署,有關詳情已送呈公司註冊處處長存檔(如法律如此規定)。

呈交者:

歐陽麗妮

職銜:

秘書 (董事、秘書或其他獲正式授權的人員)

第 9 頁共 10 頁

v 1.2.1

FF301 註 1.

香港聯交所指香港聯合交易所有限公司。

在購回股份(股份購回並註銷)及贖回股份(股份贖回並註銷)的情況下,「事件發生日期」應理解爲「註銷日期」。 在購回股份(股份被持作庫存股份)的情況下,「事件發生日期」應理解爲「發行人購回並以庫存方式持有股份的日期」。

在購回股份(股份購回擬註銷但尚未註銷)及贖回股份(股份贖回但尚未註銷)的情況下須提供相關資料。請用負數來註明於本月或早前月份購回或贖回但截至本月底尚待註銷的股 份數目。

「初始規定門檻」、「替代門檻」及「市值」的涵義按照《主板上市規則》第13.32A條或第19A.28A條 / 《GEM上市規則》第17.37A條或第25.21A條所界定。有關公眾持股量披露的 依據, 另請參閱《主板上市規則》第13.32D(4)條或19A.28D(4)條 / 《GEM上市規則》第17.37D(4)條或25.21D(4)條。

(i) 至 (viii) 項為確認內容的建議格式。上市發行人可按個別情況就不適用的項目予以修訂。如發行人早前已就某證券發行或庫存股份出售或轉讓於根據《主板上市規則》第13.25A條 / 《GEM上市規則》第17.27A條所刊發的報表中作出有關確認,則不需要於此報表再作確認。

在此「相同」指: ·

證券的面值相同,須繳或繳足的股款亦相同;

·

證券有權領取同一期間內按同一息率計算的股息/利息,下次派息時每單位應獲派發的股息/利息額亦完全相同(總額及淨額);及

·

證券附有相同權益,如不受限制的轉讓、出席會議及於會上投票,並在所有其他方面享有同等權益。

第 10 頁共 10 頁

v 1.2.1

Prompts

HUA Medicine (ticker 2552), listed in Hong Kong.

ETFs Holding HUA Medicine

ETF Weight in ETF Shares Market value As of
AVES 0.01% 437,000 $ 114.77K Nov 16, 2026
DFEM 0.00% 260,500 $ 73.056K Nov 12, 2026
DFAE 0.00% 142,500 $ 39.964K Nov 12, 2026
DFAX 0.00% 178,500 $ 50.06K Nov 12, 2026
AVEM 0.00% 628,000 $ 164.932K Nov 16, 2026
AVEE 0.00% 6,000 $ 1,575.78 Nov 16, 2026